Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $50.1900 (2.32%) ($50.1900 - $50.1900) on Mon. Mar. 22, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.32% (three month average) | RSI | 61 | Latest Price | $50.1900(2.32%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 0.9% a day on average for past five trading days. | Weekly Trend | TGTX advances 5.5% a week on average for past two weeks. | Market Behavior | Growth stock rally for large cap. Value stock sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(67%) ARKG(63%) ARKK(59%) IWO(59%) IBB(58%) | Factors Impacting TGTX price | TGTX will decline at least -1.66% in a week (0% probabilities). VIXM(-41%) VXX(-36%) UUP(-18%) UNG(-3%) IGOV(-2%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.66% (StdDev 3.32%) | Hourly BBV | 1.3 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $48.11(4.32%) | 10 Day Moving Average | $48.1(4.35%) | 20 Day Moving Average | $45.97(9.18%) | To recent high | -7.8% | To recent low | 20.4% | Market Cap | $6.357b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |